Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
In this blog, we will break down how GLP-1 medications may influence energy availability, muscle mass, workout performance, and recovery timelines, and what active adults can do to protect performance while still reaching their weight loss goals
Instead of thinking about a full dinner plate, think about a smaller formula: protein, gentle carbs, color, and fluids
A recent study from Johns Hopkins University researchers has raised questions about whether widely prescribed GLP-1 receptor agonists, including Ozempic, Wegovy, and Mounjaro, may be associated with an increased risk of dementia and Alzheimers disease